Complement System
The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.
The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.
All Product Categories
-
Complement System Inhibitors
(133)
View all products
-
Complement System Agonists
(13)
View all products
-
Complement System Antagonists
(21)
View all products
-
Complement System Activators
(7)
View all products
-
Complement System Modulator
(1)
View all products
-
Complement System Controls
(2)
View all products
-
Complement System Ligands
(3)
View all products
-
Complement System Proteins
(113)
View all products
-
Complement System Related Products (211)
Related Products (211)
-
Recombinant Proteins (113)
-
Antibodies (7)
-
AKIR001
0 ImagesCat. No.: HY-P991922AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6. AKIR001 carries LALA-silencing mutations in its FcγR-binding domain to reduce FcγR and C1q interactions, minimizing tissue interactions and limiting CDC and ADCC risks. [177Lu] radiolabeled AKIR001, namely [177Lu]Lu-AKIR001, has anticancer activity against epidermoid carcinoma.
-
MK-4721
0 ImagesCat. No.: HY-P991229Synonyms: AGS-1C4D4; AGS-PSCA
-
SAR-443809
0 ImagesCat. No.: HY-P992456SAR-443809 is a monoclonal antibody targeting complement factor Bb that inhibits the alternative complement pathway. SAR-443809 blocks the cleavage of C3 and factor B via selective binding to the activated form factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for research on hematological and renal disorders mediated by abnormal alternative complement pathway activity.
-
ANX-M1 (Mouse IgG1)
0 ImagesCat. No.: HY-P992512ANX-M1 Mouse IgG1 is a brain-penetrant C1q inhibitor. ANX-M1 Mouse IgG1 blocks classical complement pathway activation, reduces C1q concentrations in brain and plasma, and inhibits microglia-mediated synapse engulfment. ANX-M1 Mouse IgG1 can be used for the research of Huntington's disease, Alzheimer's disease, retinopathy and neuropathic pain.
-
Omoprubart
0 ImagesCat. No.: HY-P990753CAS No.: 2763342-87-4Synonyms: CAN-106Omoprubart is an anti-C5 complement recombinant humanized monoclonal antibody. Omolubat can prevent C5 from cleaving into C5a and C5b, thereby inhibiting the formation and activation of the C5b-dependent membrane attack complex (MAC) on the surface of susceptible cells, leading to cell lysis (destruction). Omoprubart can be used for the study of paroxysmal nocturnal hemoglobinuria (PNH).
-
Anti-CD55 Antibody
0 ImagesCat. No.: HY-P991962Purity: 99.76%
-
BCX 1470
0 ImagesCat. No.: HY-50874CAS No.: 217099-43-9BCX 1470 inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin.
-
Vonaprument
0 ImagesCat. No.: HY-P992142CAS No.: 3050549-24-8Synonyms: ANX-007Vonaprument is an intravitreally injected C1q antibody fragment, which is a human monoclonal antibody. Vonaprument is applicable to research related to age-related macular degeneration.
-
Anti-Complement Factor P/Properdin Antibody
0 ImagesCat. No.: HY-P990378Purity: 98.04%Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
-
Cyclosporin A-d12
0 ImagesCat. No.: HY-B0579S5Synonyms: Cyclosporine A-d12; Ciclosporin A-d12; CsA-d12Cyclosporin A-d12 (Cyclosporine A-d12) is the deuterated-labeled Cyclosporin A (HY-B0579). Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM. Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion.
-
Dexamethasone-d4
0 ImagesCat. No.: HY-14648S2CAS No.: 2305607-27-4Synonyms: Hexadecadrol-d4; Prednisolone F-d4Dexamethasone-d4 is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
-
Sefaxersen sodium scrambled negative control
0 ImagesCat. No.: HY-148370CSefaxersen sodium scrambled negative control is the sequence scrambled negative control of Sefaxersen sodium.
-
Complement factor D-IN-2
0 ImagesComplement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases.
-
Cemdisiran sodium scrambled negative control
0 ImagesCat. No.: HY-145720CCemdisiran sodium scrambled negative control is the sequence scrambled negative control of Cemdisiran sodium.
-
Iptacopan TFA
0 ImagesCat. No.: HY-127105BCAS No.: 1644670-38-1Synonyms: LNP023 TFAIptacopan (LNP023) TFA is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan TFA exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan TFA can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G).
-
Sefaxersen
0 ImagesSynonyms: IONIS-FB-LRx; RG6299; ISIS 696844Sefaxersen (IONIS-FB-LRx) is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). Sefaxersen effectively reduces circulating levels of CFB. Sefaxersen can be used for geographic atrophy (GA) research.
-
Agazisiran
0 ImagesCat. No.: HY-177611CAS No.: 2985646-78-2Agazisiran, a siRNA,is a complement factor B synthesis reducer.
-
CM05
0 ImagesCat. No.: HY-P10274CAS No.: 3037805-45-8CM05 is a bromo-fatty acid. CM05 can be used to modify ornithodoros moubata complement inhibitor (OmCI) and extend the half-life of OmCI.
-
[DArg10, Aib20] TLQP-21
![[DArg10, Aib20] TLQP-21](https://file.medchemexpress.com/product_pic/hy-p1345c.gif "Click to View [DArg10, Aib20] TLQP-21 Product Detail")
0 ImagesCat. No.: HY-P1345C[DArg10, Aib20] TLQP-21, TLQP-21 (HY-P1345) analogue, is a C3aRpartial agonist, C3aR functional antagonist (EC50: 854 nM for β-arrestin recruitment). [DArg10, Aib20] TLQP-21 shows no significant calcium flux activity. [DArg10, Aib20] TLQP-21 shows no activity in potentiating adrenergic-induced lipolysis. [DArg10, Aib20] TLQP-21 can be used in the research of inflammatory diseases, metabolic disorders, and neurological conditions.
-
Eps8 peptide 327
0 ImagesCat. No.: HY-P10994CAS No.: 1988684-26-9Synonyms: Eps8(327-335)Eps8 peptide 327 is an HLA-A*2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models.
